Reversal of Atrial Substrate to Prevent Atrial
Atrial FibrillationA multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on recurrence of atrial fibrillation.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria: Patients with symptomatic (CCS-SAF ≥2) paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and at least two of the following:
* BMI ≥ 27,
* BP ≥140/90 mmHg or history of hypertension,
* Prior stroke/transient ischemic attack,
* Diabetes,
* Heart failure (prior heart failure admission or left ventricle ejection fraction (LVEF) \<40%),
* Age ≥ 65 years
* Current smoker
* Excessive Alcohol use
Exclusion Criteria:
* Permanent AF (AF lasting \> 3 years)
* Prior catheter ablation for AF
* New York Heart Association (NYHA) Class IV (Severe) heart failure,
* Participation in a cardiac rehabilitation program within the last year,
* Currently performing exercise training \>150 minutes/week of moderate to vigorous physical activity,
* Unable to exercise,
* Unable to give informed consent,
* Other noncardiovascular medical condition making 1 year survival unlikely,
* Less than 18 years of age.
Lieu de l'étude
St. Paul's Hospital
St. Paul's HospitalVancouver, British Columbia
Canada
Contactez l'équipe d'étude
St. Mary's General Hospital
St. Mary's General HospitalKitchener, Ontario
Canada
Contactez l'équipe d'étude
Umjeet Jolly
Umjeet Jolly, MD, FRCPC
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
Eugene Crystal
Eugene Crystal, MD, FRCPC
Sacre Coeur Hospital
Sacre Coeur HospitalMontreal, Quebec
Canada
Contactez l'équipe d'étude
Marcio Sturmer
Kelowna General Health
Kelowna General HealthKelowna, British Columbia
Canada
Contactez l'équipe d'étude
Chris Lane, MD, FRCPC
Chris Lane
Hamilton Health Sciences Center
Hamilton Health Sciences CenterHamilton, Ontario
Canada
Contactez l'équipe d'étude
Jorge Wong, MD, FRCPC
Jorge Wong
St. Michael's Hospital
St. Michael's HospitalToronto, Ontario
Canada
Contactez l'équipe d'étude
Iqwal Mangat, MD, FRCPC
Iqwal Mangat
Montreal Heart Institute
Montreal Heart InstituteMontreal, Quebec
Canada
Contactez l'équipe d'étude
Lena Rivard, MD, FRCPC
Lena Rivard
Foothills Hospital
Foothills HospitalCalgary, Alberta
Canada
Contactez l'équipe d'étude
Stephen Wilton, MD, FRCPC
Stephen Wilton
Saint John Regional Hospital
Saint John Regional HospitalSaint John, New Brunswick
Canada
Contactez l'équipe d'étude
Satish Toal
Mazankowski Alberta Heart Institute
Mazankowski Alberta Heart InstituteEdmonton, Alberta
Canada
Contactez l'équipe d'étude
Ken Quadros
London Health Sciences Center
London Health Sciences CenterLondon, Ontario
Canada
Contactez l'équipe d'étude
Allan Skanes, FRCPC
Allan Skanes
QE II Health Sciences Centre
QE II Health Sciences CentreHalifax, Nova Scotia
Canada
Contactez l'équipe d'étude
Ratika Parkash
Ratika Parkash, MD MSc
Ottawa Heart Institute
Ottawa Heart InstituteOttawa, Ontario
Canada
Contactez l'équipe d'étude
David Birnie
David Birnie, MD, FRCPC
Laval Hospital
Laval HospitalLaval, Quebec
Canada
Contactez l'équipe d'étude
Regina General Hospital
Regina General HospitalRegina, Saskatchewan
Canada
Contactez l'équipe d'étude
Omar Sultan
Omar Sultan, MD, FRCPC
McGill University Health Centre
McGill University Health CentreMontreal, Quebec
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Nova Scotia Health Authority
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT03682991